Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
Transgenic Model Generation Technologies: Regular, PiggyBac, & BAC Platforms
Choosing the right transgenic platform is essential for achieving optimal transgene expression, handling complex genomic loci, and meeting project timelines. Our comprehensive transgenesis suite offers tailored solutions, ranging from cost-effective conventional methods to high-fidelity, single-copy large fragment integrations, to accelerate your exploratory and preclinical research.

Technology Selection Matrix

Maximizing the value of your genetically engineered model requires balancing genomic stability with biological fidelity. While conventional transgenesis can efficiently achieve transgene expression, more sophisticated applications often require carefully selected integration strategies to better replicate native gene regulation and physiological function.

To help identify the most appropriate platform for your research objectives, we evaluate each transgenesis technology across four key criteria:

  • Integration Strategy: Random versus transposase-mediated integration, and multi-copy versus single-copy insertion, to balance expression level, genomic stability, and reproducibility.
  • Payload Capacity: Compatibility with constructs ranging from standard plasmids to large bacterial artificial chromosomes (BACs) containing complete genomic loci.
  • Biological Performance: Ability to maintain stable transgene expression while preserving native regulatory elements and minimizing position effects or transcriptional silencing.
  • Project Timeline: Production timelines optimized for routine studies or accelerated programs with defined delivery schedules.

The comparison matrix below summarizes the technical capabilities and project timelines of our three core transgenesis platforms.

Platform Integration Strategy Payload Capacity Biological Performance Typical Turnaround
Regular Transgenesis Random, Multi-copy Plasmid & BAC (>100 kb) Highly economical; strong multi-tissue expression 2-5 Months
PiggyBac Transgenesis Random, Single-copy Plasmid & BAC (100-300 kb) Consistent expression; avoids silencing & rearrangements 8-10 Weeks (Basic) / Up to 16 Weeks (Guaranteed)
BAC Transgenesis Random, Multi-copy Up to 300 kb Preserves native regulatory elements & complex human loci Screened based on project specifications

Overview

{{static_tabs[0].title}}

Regular transgenesis is a widely used method for generating rodent models with strong transgene expression. Through pronuclear injection, it enables in vivo studies of gene overexpression and regulatory elements.

Reliable and Cost-Effective
Reliable and Cost-Effective
A proven, economical choice ideal for exploratory research.
Flexible Construct Options
Flexible Construct Options
Supports plasmid and BAC vectors for small to large (greater than 100kb) transgenes.
Fast and High Expression
Fast and High Expression
Generate founders in 2-5 months with strong, multi-tissue transgene expression.

How Regular Transgenesis Works

In regular transgenesis, linearized DNA constructs are microinjected into the pronucleus of fertilized mouse or rat embryos. These constructs integrate randomly into the host genome, typically in multiple copies, and result in hemizygous expression of the transgene. The founders are screened for integration and expression, then bred for colony expansion or experimental use.

Integration and Expression Characteristics

  • Random genomic integration with multi-copy insertion per site.
  • Variable expression patterns among founders.
  • Often strong expression in early generations, with potential for position-effect variegation due to integration site randomness.

Primary Applications

  • Gene overexpression or dominant-negative constructs.
  • Tissue-specific expression using conditional promoters.
  • Large DNA insertions via BAC vectors.
BAC (Bacterial Artificial Chromosome) transgenesis enables insertion of large genomic fragments, such as full genes with regulatory elements, into rodent genomes, ensuring faithful expression and supporting complex loci that are hard to replicate by other methods.
Suited for Complex Targets
Suited for Complex Targets
Optimized for full-length human genes and loci with complex control regions.
Large Fragment Delivery
Large Fragment Delivery
Supports plasmid and BAC vectors for small to large (greater than 100kb) transgenes.
Genetic Stability
Genetic Stability
Single-copy maintenance in bacteria ensures construct integrity and stable transmission.

How BAC Transgenesis Works

BAC transgenesis involves injecting bacterial artificial chromosome constructs into fertilized zygotes. These BACs carry large genomic regions, including promoters, exons, introns, and enhancers, enabling expression patterns that closely mimic native gene regulation. Because the integration is random and multicopy, BAC models are typically screened for expression and copy number.

Technical Distinction: Compared to knockin strategies using homologous recombination or gene editing, BAC transgenesis allows the introduction of entire genes without modifying endogenous loci, making it ideal for exploratory or overexpression studies.

Primary Applications

  • Studying intact human gene expression.
  • Investigating long-range regulatory interactions.
  • Analyzing noncoding RNAs in their native context.
  • Delivering multigene constructs that exceed the capacity of conventional vectors.
{{static_tabs[2].title}}
Our PiggyBac transgenesis platform enables efficient generation of stable, single-copy transgenic rodent models with consistent gene expression. It offers a reliable and cost-effective alternative for studying gene function and overexpression in vivo.
Flexible Design
Flexible Design
Supports both plasmid and BAC-based constructs for diverse applications.
Consistent Expression
Consistent Expression
Ensures stable, reproducible transgene expression across tissues.
Single-Copy Integration
Single-Copy Integration
Minimizes silencing and variability by inserting one precise copy per site.

How PiggyBac Transgenesis Works

PiggyBac transgenesis introduces a defined DNA fragment into the genome via pronuclear injection. Unlike traditional methods, it integrates a single copy of the transgene without vector backbone or sequence truncation, resulting in more stable and predictable expression patterns.

Workflow Highlights

PiggyBac-on-BAC: Enhanced Large Fragment Delivery

For researchers requiring large genomic regions with regulatory elements, our PiggyBac-on-BAC method combines the capacity of BACs (approximately 100 to 300 kb) with the single-copy fidelity of PiggyBac. This enables faithful gene expression patterns while avoiding multi-copy integration artifacts commonly seen in conventional transgenics.

Primary Applications

This platform is especially suited for in vivo studies requiring stable, high-fidelity expression of transgenes. Its ability to support single-copy integration with minimal disruption makes it ideal for:

  • Gene function analysis and regulatory element studies.
  • Therapeutic gene delivery validation.
  • Modeling human diseases, including those involving large or complex sequences like lncRNAs.
{{static_tabs[3].title}}

General & Technical Comparisons

What is the difference between PiggyBac transgenesis and conventional pronuclear injection?

PiggyBac transgenesis typically enables stable single-copy transgene integration with minimal vector backbone contamination. Compared with conventional pronuclear injection, it often produces more predictable transgene expression and reduces the risk of multicopy concatemer formation.

What is the difference between BAC transgenesis and knockin mouse models?

BAC transgenesis randomly integrates a bacterial artificial chromosome (BAC) into the genome without modifying the endogenous gene locus. In contrast, knockin mouse models precisely insert or replace DNA sequences at a specific genomic location.

Can regular transgenic mouse technology be used for gene knockin or conditional knockout?

No. Regular transgenesis randomly inserts a transgene into the genome and cannot generate targeted knockin or conditional knockout models. For precise genome engineering, technologies such as Targeted Gene Editing or TurboKnockout® are recommended.

DNA Constructs & Insert Size

What DNA constructs can be used for regular transgenic mouse generation?

Regular transgenesis supports both standard plasmid vectors and BAC constructs. Plasmids are ideal for small to medium-sized transgenes, while BAC vectors can carry large genomic DNA fragments of up to approximately 300 kb.

Can PiggyBac integrate large DNA fragments?

Yes. PiggyBac can efficiently integrate large DNA fragments, especially when combined with BAC constructs using our PiggyBac-on-BAC platform for large genomic insert delivery.

How large can a BAC transgene be?

BAC constructs can typically carry genomic DNA inserts of up to 300 kb, including coding sequences, promoters, enhancers, and other regulatory elements.

Can BACs reproduce natural expression patterns?

Yes, due to the inclusion of distant enhancers and other cis-elements, BACs often drive expression mimicking endogenous patterns.

Transgene Copy Number & Integration

How many transgene copies are typically inserted during regular transgenesis?

Regular pronuclear transgenesis commonly results in multiple tandem copies of the transgene integrating at a single genomic site. While this may increase expression levels, it can also lead to transgene silencing or variable expression.

Is transgene integration random in regular transgenesis?

Yes. Regular transgenesis uses random genomic integration, which may cause position effects or disrupt endogenous genes. Screening multiple founder lines is therefore recommended.

Are BAC constructs stable during transgenic mouse production?

Yes. BAC vectors are maintained as single-copy plasmids in E. coli, providing excellent stability during cloning, recombineering, and large-scale transgenic projects.

Timelines & Quality Control

How long does regular transgenic mouse generation take?

Founder mice are typically delivered within 2–5 months, depending on construct complexity, animal strain, and project requirements.

What is the turnaround time for PiggyBac transgenic mouse generation?

Standard PiggyBac transgenic mouse projects are generally completed within 8–10 weeks, while guaranteed founder delivery may require up to 16 weeks.

Which mouse strains are supported for PiggyBac transgenesis?

PiggyBac transgenesis is routinely performed in C57BL/6 mice. Additional mouse strains and rat models are also available upon request.

Is PiggyBac suitable for therapeutic gene validation studies?

Yes. PiggyBac transgenic mouse models are widely used for stable overexpression of therapeutic genes and preclinical proof-of-concept studies because of their reliable genomic integration.

How are BAC constructs quality controlled before microinjection?

Each BAC construct undergoes rigorous quality control, including BAC recombineering, full construct validation, and optional genotyping strategy design before embryo microinjection.
Key advantages
Flexible Platform Selection
Choose from regular, BAC, and PiggyBac transgenesis to match your construct size, expression requirements, and research goals.
Support for Large and Complex Constructs
Accommodate standard plasmids, full-length genes, regulatory elements, and genomic fragments of up to 300 kb.
Reliable Transgene Expression
Select between strong multicopy expression and stable single-copy integration for improved consistency and reproducibility.
Efficient Project Delivery
Flexible workflows and optimized timelines support both exploratory studies and accelerated preclinical programs.
Related Resources
Events & Webinars
Beyond the mouse: Accelerating Drug Discovery for Obesity & T2D with HUGO-GT™
View Details
Promotional Campaign
Flash Drop — Ready-to-Ship KO/cKO Mice
View Details
Blogs & Insights
Accelerating Alzheimer's Research Using Advanced iPSC Platforms
View Details
Resource Valut
Development of Fully Human Anti-ACVR2A Antibodies with Enhanced Selectivity and Favorable Pharmacokinetics for Metabolic and Muscle Disorders
View Details
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Inquiry Details
Main Area of Research
Service(s) of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research